in partnership with tec edmonton, bioalberta celebrates ... documents/hlss pro… · ocular...

In partnership with TEC Edmonton,

BioAlberta celebrates our

19th annual AGM and Awards Gala

with the Health and Life Sciences Showcase

Monday 24 September 2018

BMO Centre, Stampede Park, Calgary

BioAlberta’s signature event is a gathering

of key industry stakeholders.

We will honour the

founders, researchers and entrepreneurs

of Alberta’s Life Sciences Industry.

#BioAlbertaShowcaseAwards2018



AGM, SHOWCASE & GALA AGENDA

9:00 – 10:15 BioAlberta Board Meeting – QUARTERHORSE A

10:30– 11:30 BioAlberta AGM – PALOMINO A

1:00 – 1:25 Opening Remarks – PALOMINO D&E

1:30 – 4:30 Investment Pitches, Industry Roundtables and One-on-One Partnering (details below)

4:00 – 6:00 Table Displays - LOBBY

5:00 – 6:00 Networking and Reception - LOBBY

6:00 – 9:00 Gala Dinner and Awards Presentations – PALOMINO D & E

INVESTMENT PITCHES & INDUSTRY ROUNDTABLES

TIME PALOMINO A PALOMINO B PALOMINO C

1:30 – 2:45 Investment Pitch

Health IT & Med Tech

Roundtable

Natural Health Products One-on-one Partnering

2:45 – 3:00 Break Break Break

3:00 – 4:30 Investment Pitch

Health IT & Med Tech

Roundtable

Institute of Health Economics One-on-one Partnering



MORNING AGENDA

BioAlberta Board Meeting 9:00 – 10:15 AM

BioAlberta Annual General Meeting 10:30 – 11:30 AM

AFTERNOON AGENDA

Opening Remarks 1:00 – 1:30 PM

Afternoon Sessions 1:30 – 4:30 PM

Life Sciences Pitch Sessions

Companies in health IT and medical technology sectors pitch to a panel and audience of investors. Companies

have 10 minutes to pitch and five minute Q&A by panel and facilitator. This will be broken into two sessions.

Facilitator: Greg Klak, General Manager, Gilead Alberta ULC and BioAlberta Board Member

COMPANIES PITCHING:

1. Clinisys EMR Inc.

2. Elsius Biomedical Corporation

3. MagnetTx Oncology Solutions

4. Metabolomics Technology Inc.

5. Neuraura Biotech

6. SafeTracks GPS Canada Inc.

7. Salu Design Group Inc.

8. Think Tank Innovations (ShareSmart)

9. Tevosol

10. Zenxmed Innovations Inc.

CONFIRMED INVESTORS:

1. Acuris Partners

2. Accel-Rx

3. ATB Financial

4. Brass Dome Ventures

5. Builders VC

6. Connection Silicon Valley

7. Flagship Pioneering

8. GE Healthcare

9. Greybird Ventures

10. Kensington Capital

11. NeuroCrunch

12. Radiant Health Advisors

13. RBC

ANGEL INVESTORS:

1. Hatim Chraibi

2. Konstatin Kostov

3. Larry Miller

4. Ziad Moukheiber

https://www.linkedin.com/in/samuelswu

http://trk.cp20.com/click/iczq7-bgpsk4-5l2mt2l6/

http://www.builders.vc/

http://www.connectionsiliconvalley.com/

http://www3.gehealthcare.ca/

http://www.kcpl.ca/

https://www.linkedin.com/in/kaushik-srinivasan-4a384952

ttp://commercial.rbcroyalbank.com/stephen.donovan



I N V E S T O R S

Accel-Rx

Michael Lincoln, Chief Financial and Business Officer, Accel-Rx currently serves as

Chief Financial and Business Officer at Accel-Rx Health Sciences Accelerator. He has

over twenty-five years of senior management experience in the biotechnology and

pharmaceutical industry from start-ups to multi-national pharmaceutical companies.

Michael has extensive experience in finance and business development and has a track

record of supporting the growth of small and medium size businesses through all stages

of development. Previous experience includes public and private equity financing, IPO,

investor relations, licensing of technology, M&A activity, joint ventures, and the

licensing of numerous branded products.

Prior to joining Accel-Rx, Michael was the Chief Financial and Business Officer at CDRD Ventures Inc., Chief

Financial Officer & Senior Vice President at MedGenesis Therapeutix Inc., Vice-President of Business

Development at Transition Therapeutics Inc. and has held various management positions at Altimed

Pharmaceuticals and Merck Frosst Canada.

Mr. Lincoln earned his Master of Business Administration degree, and a Bachelor’s degree in Economics from

Concordia University, Montreal, QC, and is a Chartered Professional Accountant (CMA).

Acuris Partners

Samuel Wu has been a healthcare venture capital investor since 2002. He is a

founding partner at Acuris, which was recently launched by the MedImmune

Ventures team out of AstraZeneca. Previously he was the managing director of

MedImmune Ventures’ West Coast office from 2010 to 2016, and a principal at SV

Life Sciences, where he invested in a broad range of biopharmaceutical, platform

and medical device companies. Sam is or has been a board member of Applied

Genetic Technologies Corp (NASDAQ:AGTC), Cerapedics, Hydra Biosciences,

Ocular Therapeutix (NASDAQ:OCUL), and the California Life Sciences Institute.

Prior to his VC career, he was an Engagement Manager with McKinsey and Company, leading teams of

consultants serving life science clients on M&A, portfolio analysis and other strategic issues.

Sam holds a B.A. magna cum laude in Biochemistry from Harvard University, attended Stanford University

School of Medicine where he earned an M.D. and a Ph.D. in Biochemistry as a Howard Hughes Fellow, and

trained in Internal Medicine at the University of California, Los Angeles.

https://www.linkedin.com/in/samuelswu



ATB Financial

Sasha Musij - A passion for pioneering growth in Alberta’s constantly evolving

agricultural landscape plays a key role in Sasha’s approach to building the most

effective financial solutions for ATB’s agribusiness clients, tailored to their specific

needs. This includes everything from pre-farm sciences and technologies through to

post farm gate production, manufacturing and innovation. His support extends to

being a thought leader, connecter, catalyst and lender to the agribusiness ecosystem

throughout Alberta.

Prior to joining ATB, Sasha worked with Calgary Economic Development as the Business Development

Manager for Agribusiness. He designed and implemented their Agribusiness strategy under the 10-year

Economic Strategy, which had a mandate to support the city's diversified sectors. The primary focus of this

role was designed around the development of a business enabling ecosystem that would strengthen investment

attraction, expansion opportunities and overall policy. Within this role Sasha worked with the full value chain

of Agribusiness from large corporations to SME’s and startups involved in pre-farm sciences/inputs,

agritechnologies, professional and financial services and food and beverage manufacturing.

Business is personal, and creating strong relationships is critical to providing the right service. “The more

you understand operational needs and motivations, the better you can align them with offerings to serve them

best,” Sasha says. “My goal is to find out what’s best for the client and move forward with the right solution

to achieve the desired results, now and well into the future.”

An avid outdoor enthusiast, Sasha’s passion for the agribusiness sector stems from his love for the outdoors,

discovering where our food comes from and exploring innovations that provide us sustainable solutions.

Whether its spending time in the mountains or driving through the prairies, his curiosity for the natural

ecosystem has driven his interest in supporting the full agribusiness value chain.

https://www.atb.com/Pages/default.aspx



Brass Dome Ventures

Christopher Micetich – Founder, President & CEO of Brass Dome Ventures

Ltd., a business to business consultation company offering assistance to many

companies across many industries. The company employs a proven team of

administrative experts with a long track record of success specializing in a wide

variety of business areas. Chris is also Founder, President & CEO of Fedora

Pharmaceuticals Inc., a pharmaceutical drug discovery company specialized in

the area of infectious diseases. In December 2012, Fedora signed the largest

licensing deal ever signed in Canadian biotech history licensing their beta-

lactamse inhibitor discovery program to Hoffman J. La Roche for milestone

payments of US$750,000 in addition to double digit royalties. Chris was also

Founder, President & CEO of numerous companies including:

Naeja Pharmaceuticals Inc., was a contract drug discovery company offering chemistry and biology services to

over 100 companies around the world. Naeja was, for many years, the largest employer of PhD’s in Canada

employing 130 full time employees. . Naeja employees were contributors to +500 patents and publications in

numerous areas of research.

DrisCorp Inc.was a drug discovery company offering chemistry research services to the pharmaceutical

industry. DrisCorp employed over 35 PhD chemists offering chemistry services to several large pharmaceutical

companies around the globe. The creation of Naeja led to the rolling over of DrisCorp’s contracts and

employees before the eventual acquisition of the company by Brass Dome Group Inc.

Windjammer Java Roasters Inc. was a specialty gourmet coffee roasting company offering both retail and

wholesale coffee beans to consumers. Raw green coffee beans from around the globe were imported, roasted

and sold. Windjammer’s niche was dating the roasted coffee and donating any coffee beyond two weeks from

the date of roasting to homeless people through the Mustard Seed Church. The company assets were eventually

sold before rolling Windjammer into Brass Dome Group Inc.

Chris was also COO of SynPhar Laboratories Inc. a joint venture company created between Ronald G. Micetich,

Canada and Taiho Pharmaceutical Company Ltd., Japan. The joint venture was the first ever signed between a

Canadian individual and a Japanese company. Christopher joined the company at inception and contributed to

the growth from 4 to 65 employees. SynPhar was responsible for +120 compositional matter patents in

numerous areas of research and boasts two drugs on the market today along with numerous still in development.

http://trk.cp20.com/click/iczq7-bgpsk4-5l2mt2l6/



Builders VC

Jim Kim, General Partner, is a founding member and GP of Builders VC.

Prior to Builders, Jim founded Formation 8 and served as its Managing

Partner. Jim enjoys investing in entrepreneurs working on transformative,

contrarian companies. He currently serves on the boards of IT and

Diversified Technology companies including: Context Relevant, EVA,

Bolt Threads Taxon Biosciences (sold to DuPont), and GrabIt, and

previously served on the boards of Wish and Lucid Design.

Prior to Formation 8, Jim was a General Partner at Khosla Ventures, where

he led investments and founded technology companies in a variety of

industries including IT, hardware, energy, and consumer products. Prior to

KV, Jim joined CMEA Capital as a Senior Partner in their E M practice.

Jim began his career with GE Capital’s Structured Finance group where he worked on a variety of IT Telecom

financings before joining the Energy Finance team and working to grow their portfolio to $15B in assets. At

GE, Jim also co-founded the GE Ventures initiative and led investments in China High Speed Transmission,

ComScore, A123 Systems, Danger, and several later-stage companies across diverse technology sectors.

Jim received undergraduate degrees in Computer Science Electrical Engineering and Political Science from

MIT, where he also founded a venture-backed Internet infrastructure start-up with fellow Course 6 students.

He also holds a Masters Degree in Quantitative Data Analysis from Columbia University and an MBA from

Columbia Business School.

Jim enjoys kung-fu, tai chi, making wine (DJK Lei), and fishing, and he hopes to see the U.S. Soccer team

win a World Cup in his lifetime.

Connection Silicon Valley

Joanne Fedeyko is the founder and CEO of Connection Silicon Valley (CSV),

an organization that helps companies collaborate, connect, innovate, and

partner with Silicon Valley's world-renowned technology ecosystem. Their

business is centered around bringing better innovation to Canada by helping

startups and large corporates leverage the best of innovation from Silicon

Valley. Joanne is a Founding Board Member of Canadian Entrepreneurs in Life

Sciences (CELS) --- a nonprofit organization supporting the advancement of

Canadian life science technology businesses by access to connections,

community and capital in the San Francisco Bay Area.

https://www.builders.vc/

http://www.connectionsiliconvalley.com/



Flagship

Pioneering

Avak Kahvejian joined Flagship Pioneering in 2011, focusing on internal

biotechnology innovation and venture creation. Avak was on the founding teams

of Seres Therapeutics and Codiak BioSciences, and he is a co-founder of Rubius

Therapeutics. Currently, Avak serves as founding president and CEO of Cygnal

Therapeutics, a company pioneering the field of exoneural biology for the

treatment of cancer, autoimmunity and other diseases.

Prior to Flagship, Avak was at Helicos BioSciences, a Flagship VentureLabs

company which developed and commercialized the world’s first single molecule

sequencing technology.

At Helicos since 2004, Avak held various business development, product management, marketing and sales

roles. Most recently, as vice president, business development for Helicos, he focused on establishing strategic

partnerships in the areas of high-throughput sequencing and molecular diagnostics, leveraging the technology’s

unique capabilities.

Avak earned his Ph.D. from McGill University in the laboratory of Dr. Nahum Sonenberg, where his research

focused on modulators of mRNA translation and their regulation. During his studies at McGill, Avak was

awarded a Canadian Institutes of Health Research operating grant as a co-investigator to Dr. Sonenberg, and

was selected for the Dean’s Honor List upon graduation.

As a member of the Board of Directors for Canadian Entrepreneurs in New England (CENE), Avak has

reviewed, selected, and mentored numerous promising Canadian startups to help them tap into Boston's

innovation ecosystem. CENE is a nonprofit, member-driven organization dedicated to empowering Canadians

to grow successful businesses globally.



GE Healthcare

•

Dr. Dan Zikovitz, Principal Solutions Architect – is currently a Principal

Digital Solutions Architect at GE Healthcare Canada with national

responsibility working with customers to achieve meaningful outcomes

through Big Data and Analytics. With over 20 years of Healthcare experience

coupled with extensive experience in data and analytics and software

development, his approach has been used to solve challenges that hospitals are

facing around the world.

He serves as a Digital Ambassador for GE Healthcare Canada supporting several businesses across Canada

providing customer support as well as a conduit into GE-Digital international.

Daniel holds advanced degrees in Biology and Computer Science from York University’s Centre for Vision

Research developing computer models of how the human brain perceives self-motion through several senses

modelled as sensors. He has held teaching appointments in the faculties of Biology, Psychology and Computer

Science. A Certified Modeling and Simulation Professional, he has delivered over fifty articles and platform

presentations

http://www3.gehealthcare.ca/



Greybird Ventures

Tom Miller, after receiving a degree in Nuclear Engineering from the University

of Massachusetts at Lowell, studied Medical Physics at the Harvard/MIT Health

Sciences and Technology joint program graduating with a Masters degree in

1982. During his academic career he worked at Los Alamos, the Swiss Institute

for Nuclear Research (now the Paul Scherer Institute), Brookhaven National

Laboratory, and the Massachusetts General Hospital as a research associate in

radiation biophysics.

Tom then joined Siemens Medical Systems where, after 9 years, he became the

first non-German CEO of a German factory and business unit. He left Siemens

after 15 years to become CEO of the global medical operations of Carl Zeiss.

Completing a successful turnaround, he joined Analogic Corporation as CEO. After three years and a doubling

of the stock price, Tom left to become CEO of LightLab Imaging, a start-up that he helped to establish.

Completing a profitable sale of LightLab to a Japanese company, Tom re-joined Siemens eventually serving as

a member of the operating board of Siemens Healthcare and the CEO of the Customer Solutions Division,

responsible for 26,000 employees in over 130 countries.

In 2013, Tom started GreyBird Ventures, an investment firm focused on emerging technologies for precision

medicine diagnosis. He currently serves as board chairman or independent director on the boards of five medical

technology companies.

Tom is a frequent speaker on healthcare technology and business at such venues as the National Press Club, the

National Library of Medicine, the National Institute of Health, and the American Hospital Association. He was

selected by the diagnostic imaging industry to provide Congressional testimony to the House Health Sub-

Committee in June of 2009 and to speak on breast cancer technology at the European Parliament in 2012.

Sponsored by the American Hospital Association, Tom gave the keynote at the Health Executive Forum in

Arizona in 2013 on sustainable healthcare and Precision Medicine and authored an article for Arab Health

Magazine summarizing a keynote speech given at the 2013 Arab Health meeting in Dubai on the same topic.

Tom’s international reputation gave him the honor of giving the 2013 commencement address at the India

Institute of Technology in Roorkee, and keynote addresses to the Chinese Private Hospital Association in 2014

in Wuhan, the Innovation for Health Conference in 2015 in Amsterdam, the 2015 TiE Leapfrog Conference in

Bangalore, the 2016 World Executive Healthcare Forum in Montreal, and in 2017 he both organized and spoke

at the first Precision Medicine in Oncology Conference in Tianjin China as well as the Harvard Personalized

Medicine Conference.



Kensington Capital

Dylan Freeze is an Analyst on Kensington’s venture capital investment team,

based in Vancouver.

Dylan’s career began as an Analyst at iData Research, a Vancouver Based

Market Research firm focused on the medical sector. Dylan transitioned to a role

as a Program Manager at the BC Tech Association in 2015 and quickly

immersed himself in Vancouver’s rapidly growing tech ecosystem.

He managed a program called HyperGrowth:Life which selected promising

companies and put together a year of programming and advisory board to help

accelerate their businesses

Dylan also managed BC Tech’s Connection Day program connecting out of province/country investors and

corporate partners to local technology companies. Dylan’s main areas of focus at BC Tech were

HealthTech/Life Sciences, Cleantech, and Industrial Technology.

Dylan holds a B.Sc. in Biology from the University of Victoria.

NeuroCrunch

Tim Owen is CEO of NeuroCrunch and Board President, Canadian Entrepreneurs in

New England (CENE). Tim has more than 25 years of experience in the high tech

industry. He has been a pioneer in the cloud-based software market and has held key

roles with numerous start-ups, including 3 that were acquired by larger

companies. Tim is currently the founder and CEO of NeuroCrunch, a technology

ventures company. Previously he held the role of SVP, Global Sales for rFactr, a

social selling company.

Tim thrives on helping start-up companies build high-performance sales teams and processes, early-stage

account development, grow indirect sales channels and forge strategic partnerships.

Tim is also President, Board Director, and Founding Member of The Canadian Entrepreneurs in New England

(CENE). CENE's Boston-based members share their expertise with fellow Canadians through mentorship,

investment strategy, networking and thought leadership programs. He is passionate about helping Canadian

start-ups achieve their full business potential in New England and across the US.

Tim has strong Western Canada roots. He graduated from the University of Saskatchewan and lived in Calgary

for 13 years prior to moving to Boston.

http://www.kcpl.ca/



Radiant Health Advisors

Kaushik Srinivasan is an accomplished C-Suite Executive, Consultant,

Healthcare Attorney, Medical Real Estate Developer, and Entrepreneur with

substantial success in the healthcare industry spanning clinical services,

outpatient and ancillary care, medical devices, health law, and commercial real

estate.

Throughout his executive career, Kaushik has held leadership positions with

increasing responsibility in a variety of healthcare roles. As a CEO in training

at Community Health Systems and Quorum Health, he has overseen the

operations and growth of several clinical and ancillary departments, introduced

new service lines for Orthopedics and Wound Care, led the construction of

outpatient clinics, and identified opportunities to innovate by partnering with

third-party vendors.

As the President and Managing Partner of Radiant Health Advisors, he has led due diligence analyses and

business plan developments for Fortune 500 companies, medical schools, and top universities. In addition, he

has provided legal and business consulting to various clients pertaining to mergers & acquisitions, medical

device commercialization, contract negotiations, financial valuations, and regulatory approval. In addition, he

has provided legal and business consulting to various clients pertaining to mergers & acquisitions, medical

device commercialization, contract negotiations, and financial valuations. Kaushik is licensed as an attorney in

several state and federal jurisdictions in the United States, and has leveraged his experience in health law and

regulation to be a valuable asset for startup to mid-size growth-stage companies navigating the healthcare

regulatory environment.

RBC

Stephen Donovan is a Commercial Account Manager with RBC supporting

energy and technology companies in Calgary, AB. Stephen has been with RBC

for 2 years, and prior to joining RBC spent time working in the energy and

manufacturing industries. Stephen is from Newfoundland, and is currently

completing his MBA at the University of Calgary with specializations in

finance and entrepreneurship & innovation.

https://www.radianthealthadvisors.com/

ttp://commercial.rbcroyalbank.com/stephen.donovan



A N G E L I N V E S T O R S

Hatim Chraibi is co-founder and managing director-USA at SPIRE Bioventures. With

more than 18 years experience in the medical device industry in both upstream and

downstream capacities globally, Hatim received a bachelor degree in Finance from the

University of San Francisco, and an MBA from McGill University (Exchange program

at the Luigi Bocconi University in Milan, Italy).

Before co-founding SPIRE Bioventures where he acts as Managing Director USA. SPIRE

Bioventures, is a Palo Alto and Barcelona based heath science accelerator that aims to

boost early concepts in the vibrant Canadian and European ecosystems.

Hatim has had tenures at Philips Medical Systems, Covidien and other smaller medical device companies. He

has worked on product requirements with R&D teams and key opinion leaders worldwide and built various

global organizations and contributed significantly to their international visibility and sales. Hatim has an

intimate expertise of the Medical device industry worldwide, has worked in various countries and is fluent in 5

languages.

His areas of interest and expertise include start-up mentoring in product definition/positioning, market research,

key opinion leaders’ engagement, product positioning and global distribution. Hatim is also a strategic advisor

for Typlit, a tubular ligation device in Laparoscopic procedures and DNAmito, a MtDNA diagnostic company

in precision medicine for cancer treatment. Hatim is also a mentor with the French Tech Hub in San Francisco,

CA and part of the founding team of CELS (Canadian Entrepreneurs in Life Sciences).



Larry Miller of BlueTree Allied Angels is a group of accredited investors that invests in regional, early-stage

companies. Our members-only organization operates as a network of private equity investors that meets

monthly to evaluate and consider pre-institutional investments.

Leveraging our members’ knowledge and experience helps to mitigate investment risk, thus, strengthening the

probability of investment success. Although the membership works together as a group to efficiently and

effectively evaluate investment opportunities, each member makes his or her own individual investment

decisions. In addition to our angel network, we are pleased to announce the creation of the BlueTree Venture

Fund. The Fund is a passive investment vehicle designed to allow investors to invest their capital without

investing their time.

Larry Miller, Chairman of Life Science Deal Flow Committee

As Chairman of the Life Science Deal Flow Committee, Larry leverages his strong network and background

to actively seek out promising deals and guide BlueTree’s deal screening process for all life science

companies. In addition to his work at BlueTree, Larry serves as an Executive in Residence at Innovation

Works.

As an Executive in Residence, Larry Miller works with the management teams of early stage life science or

medical device start-up technology companies. The goal is to assist the entrepreneurial community to identify

and address their critical business issues including intellectual property creation and protection, product

development, marketing, sales, fundraising, management recruitment and growth planning. For portfolio

companies, Larry provides mentoring and network access, and may serve as an observer on the Board of

Directors.

Larry has broad experience in medical device and capital equipment marketing, sales service and equipment

finance including 16 years of P&L and balance sheet management of divisions as large as $600M in sales to

as small as a skunk works product development team designing novel permanent magnet based MRI systems.

Prior to joining Innovation Works, Larry was President and CEO of Biomec, a technology accelerator and

investment company which raised over $20M in SBIR grants, and provided business development consulting

for a number of radiology product manufacturers and distributors. At Picker International and Philips Medical

systems, Larry was president of the Healthcare Products group, a $600M distributor of radiology supplies,

managed the Asia/ Pacific region for sales and service of the diagnostic imaging product portfolio, and was

president of the Picker Financial Group, a JV, captive leasing company. Other assignments include marketing

and sales of CT and MRI products for Picker and General Electric Medical Systems.



Ziad Moukheiber, Boston Harbor Angels: Angel and early stage investing in technology and life sciences

companies. M.A.I.B. _ Mentor, Advisor, Investor, Board-member.

Boston Harbor Angels is a group of proven business leaders interested in investing a portion of our assets in

high-growth, early-stage companies. Since 2004, our portfolio has included companies in information

technology, life sciences, consumer products, business products, services, specialty materials, aviation and

more. We believe we contribute more than just money to the companies we fund. We welcome the opportunity

to work with entrepreneurs who are open to taking advice, yet have the smarts and determination to make their

company successful.

Our focus is early-stage companies that are looking to raise $250K to $1.5M. We look for companies where

we can fund a portion of the round and syndicate the deal with other angel groups or early-stage venture funds.

The company should be close to the commercialization stage and have a clear and defensible competitive

advantage. We are looking for capital-efficient businesses that can reach profitability with less than $5M of

equity investment and provide at least a tenfold return on the investment within five years.

Boston Harbor Angels does not invest as a fund—each of our members makes his or her individual investment

decision. Members collaborate in due diligence. We are open to any opportunities that can make a strong

business case and can take the position of a lead investor if one of us has strong expertise within our group.

We are proud partners with Nutter McClennen & Fish LLP, MPR Product Development, The Bulfinch Group

and Babson College.

Boston Harbor Angels was founded in February 2004 by Mic Williams. Day-to-day operations are managed

by Ziad Moukheiber.



INDUSTRY SPECIFIC ROUNDTABLES 1:30 – 4:30 PM

Aim of all roundtables will be for BioAlberta to take the next steps forward in advocacy for policy development.

ROUNDTABLE 1:30 – 2:45 PM

NATURAL HEALTH PRODUCTS AND FUNCTIONAL INGREDIENTS “BRANDING THROUGH COLLABORATION”

Having an Alberta Natural Health Products Brand serves to differentiate products in the marketplace, and it

attracts and retains loyal customers. Beginning efforts could include cataloguing, participating in the

Compendium of Pharmaceuticals and Specialties (CPS), showcasing and more. Discussion at the roundtable

should involve everyone that has an interesting in Markets and Public Engagement for Natural Health Products

and Functional Ingredients.

Facilitator: Steve Jakeway Ph.D.

Steve joined Radient Technologies Inc. as the

Director, Sales and Marketing in 2017. He has

worked in business development for more than 10 years holding senior

management roles in several technology-based companies including

GrainFrac and BioNeutra. He also assisted the University of Alberta,

Department of Oncology to develop a commercialization plan for their

medical cyclotron. He has been a key account manager into many of the

world’s largest market leading companies including Intel, PepsiCo, General

Electric, Nestle, Intel, General Mills, Phillips, Roquette, and The Coca Cola

Company.

Steve has assisted many start-up companies providing assistance for operations, business development,

technical, and finance (raising almost $27M).

Steve received a Ph.D. in Analytical Chemistry (2002) from the Imperial College, University of London

(UK) where he developed a reusable microfluidic device to identify multiple different DNA stands. His

M.Sc. in Chemistry (1999) from the University of Toronto focused on the development of fiber-optic DNA

probe. In obtaining his B.Sc. in Chemistry (1996) from the University of Alberta he participated in research

on implantable electrodes for glucose monitoring as part of the larger program that led to the development

of the world-renowned Edmonton Protocol for islet transplant. Steve also serves on the board of directors

for Agriculture and Food Council (Vice-Chair) and the Association of the Chemical Professional of Alberta.



ROUNDTABLE 3:00 – 4:30 PM

INSTITUTE OF HEALTH ECONOMICS “SME EDUCATION SERIES ROUNDTABLE”

Beginning in late Fall 2018, the IHE will be providing a four-part education series for Alberta life sciences SMEs

and ecosystem partners to ensure understanding of the importance of, and requirements for, economic evaluation

to support product and business planning. Early stage companies can benefit from health economics by

understanding the 'innovation headroom' available and the commercial viability of their product, which can be

used to guide R&D focus and support capital raises. Later stage organizations can benefit from health economics

by robust documentation of their value proposition to prepare a complete and compelling evidence package

(clinical and economic) in support of procurement efforts. This Roundtable will provide an overview of the series,

and enable participants to help define the content of the series so it is most valuable to them. www.ihe.ca

Facilitator: Keith Gilchrist, Government Affairs and Market Access, Janssen Inc. and

BioAlberta Board Member

MODERATOR: Dan Palfrey, BSc. MPH

Dan Palfrey is a senior consultant working with the Institute of Health

Economics. In previous roles Dan has held progressive leadership positions with a

multinational pharmaceutical organization in Market Research, Sales, Marketing,

Product Management and Government Relations, and most recently was a Vice

President with one of Canada's leading Electronic Medical Record (EMR)

companies. Dan has Master of Public Health and Bachelor of Science degrees from the

University of Alberta and is a past recipient of the Robert Wood Johnson Award.

PRESENTER: Dr. Gareth Hopkin

Dr. Gareth Hopkin is a Research Fellow at the IHE. He obtained his PhD in Health

Services Research at King’s College London, and also holds a BSc (Hons) in Applied

Psychology from Cardiff University. Prior to joining the IHE, Gareth was a Fellow in

Health Policy at the London School of Economics, where he taught on executive and

full-time MSc courses (including economic evaluation, research design for health

policy, and measuring health system performance), alongside conducting health

services research and economic evaluations in several health areas. He has particular

interests in the impact and cost-effectiveness of health policies and complex

interventions and the health of disadvantaged and underserved populations.

http://www.ihe.ca/



ONE-ON-ONE PARTNERING 1:30 – 4:15 PM

The One on One Partnering stream will be run in a “speed-dating” format. Multinationals (MNEs) and Venture

Capitalists (VCs) will be matched with SMEs and potentially some researchers based on the multinationals’ and

VCs’ primary areas of focus. MNE and VC representatives will be seated at separated tables and SME executives

and researchers will come to them to make short, 15-minute presentations on their lead product or discovery.

Facilitator: Sharon Barker, Director, TEC Edmonton Health Accelerator

NETWORKING 4:00 - 6:00PM

Immediately following the afternoon sessions is the Vendor Showcase and Gala Reception for casual networking.

Those wishing to showcase their services or collaborations, will be able to do so around the reception area:

Vendor Showcase

Participating companies:

BioTalent Canada

Bay Area Research Laboratories

Hicks & Associates Intellectual Property

Mitacs

SafeTracks GPS Canada Inc.

NETWORKING RECEPTION 5:00-6:00PM



BioAlberta ’s 1 9 t h Annual Awards Gala 6 :0 0 - 9 :0 0 p m

Our annual gala is held to network and celebrate outstanding achievements within the industry. This premier

event brings together the membership and friends of the industry to honour achievement and celebrate the

industry’s milestones. It is always an enjoyable and memorable evening, and the successes in our industry are

acknowledged by presenting awards for: "Company of the Year" and "Scientific Achievement and

Innovation".

KEYNOTE: Jason Pincock, CEO, DynaLIFE Medical Labs and Chair, Edmonton Health City

Jason is currently the Chief Executive Officer of DynaLIFE Medical Labs, one of

Alberta’s largest private healthcare organizations. At over 1100 employees DynaLIFE

is Canada’s most regarded multidisciplinary clinical laboratory organization and is

recognized as one of Canada’s Best Managed Companies. DynaLIFE provides clinical

diagnostics to support physicians, patients, hospitals and other health providers from

central Alberta through the Territories. DynaLIFE is internationally accredited for

quality and is routinely listed as one of Albert’s Best Workplaces.

Its dedication to the community includes sponsorships and fundraising for a variety of

charities as well as support for researchers and health care start-up organizations.

Jason is a Certified Management Accountant, a graduate of the Queens Executive Program and a member of

the Institute of Corporate Directors. Jason works with an ownership board, including OMERS and Laboratory

Corporation of America (publicly traded. With a decade of experience at the executive level his background

includes roles from CFO to Government Relations. Although his professional background is financial, he is

regarded for his transparent and accountable leadership style, as a creator and driver of innovation and strategy.

Jason participates in various bio‐tech related industry groups, works with Economic Development and

participates on various community committees. Jason is currently the Vice Chair of Edmonton’s Health City

initiative and is serving on the boards of Little Warriors, Bissell Centre, and Viewics a US health analytics

company. On a personal level, Jason lives in St. Albert with a big family that includes six active children. In

between work and kids he is an active outdoorsman with passions from sailing to skiing, motorbikes to

mountains, and loves to spend time with his family in the back country or behind the boat at their cabin.



G A L A P RO G R A M Master of Ceremonies

Ms. Bridgette Duniece, VP External Affairs and Operations, Permolex Ltd. & BioAlberta Board Member

6:00 PM Welcome

6:15 PM Remarks by Government Representative

6:20 PM Dinner Service Begins

6:30 PM Announcements

*Continuation of Dinner Service*

7:20 PM Keynote Address by Jason Pincock

7:55 PM Awards Presentations Commence

Award for Company of the Year

Award for Scientific Achievement and Innovation

8:30 PM Special Recognition

8:40 PM Closing Remarks

MENU Southwestern Tortilla Salad

West Coast Grilled AAA Alberta Strip Loin Steak

Western Potato Wedge

Fresh Seasonal Vegetables

Tres Leche Flan with Seasonal berries

Cono Sur Bicicleta Sauvignon Blanc (Colchagua, Chile)

Cono Sur Bicicleta Merlot (Maule Valley, Chile)



Thank You to Our Sponsors



N O T E S



#BioAlbertaShowcaseAwards2018

With special thanks to our partners, sponsors and guests

drive safely

Please join us next year as BioAlberta celebrates our 20th

year!

1999 - 2019

in partnership with tec edmonton, bioalberta celebrates ... documents/hlss pro… · ocular...

Documents